Rosuvastatin Effect on Telomere-telomerase System in ACS

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

Also called NCT02299245

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02299245
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02299245. Randomized; no masking; primary purpose treatment. Start 2014-10 (registry gives no type); primary completion 2016-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Rosuvastatin Effect on Telomere-telomerase System in ACS
Condition
Telomere Shortening
Condition
Telomere Length, Mean Leukocyte
Condition
22q Telomere Deletion Syndrome
Intervention (Drug)
rosuvastatin
Lead sponsor
Xiao-dong Zhuang (class: other)
Collaborator
Sun Yat-sen University (class: other)

Record details

Record id
cardio:ct-nct02299245
Content hash
85522ae9088594f59eb6e7e4856b67ca222fd74c82768939ff020bafa6ceb2c0